relugolix — CareFirst (Caremark)

Initial criteria

• Authorization may be granted for treatment of prostate cancer.

Reauthorization criteria

• Member is experiencing clinical benefit to therapy (e.g., maintaining serum testosterone < 50 ng/dL) AND has not experienced unacceptable toxicity.

Approval duration

12 months